Background: Preventing the development of allergic skin disease in children is the best way to treat the disease. Objectives: Ultraviolet (UV)-free blue light phototherapy has been reported to treat atopic eczema. We evaluated the effect of neonatal phototherapy on allergic skin disease in children. Methods: We randomly recruited 117,041 children from an insurance research database. Those with neonatal jaundice and receiving neonatal phototherapy were classified as the icteric-phototherapy group (n = 4,744), those with neonatal jaundice and not receiving phototherapy were classified as the icteric-non-phototherapy group (n = 5,003), and those without jaundice were classified as the non-icteric group (= 107,294). We reviewed claims from birth to age 5 years. The prevalence of atopic dermatitis (AD), clinical visit times, and topical prescriptions for allergic skin disease at different ages were compared among groups. Results: AD prevalence was lower in the icteric-phototherapy group than in the icteric-non-phototherapy group. Moreover, clinical visit times for allergic skin disease were lower at age 1–4 years, and topical agent prescription for allergic skin disease were lower at age 1–5 years, in the icteric-phototherapy group than in the icteric-non-phototherapy group. The decreased use of topical agents could reach 64.29%. The 5-year complications of skin disease and cancer in the phototherapy group were not higher. Conclusions: To our knowledge, this is the first study to report on the effect of UV-free blue light therapy on allergic skin disease in newborns. Blue light therapy in newborns may be a novel method to efficiently prevent allergic skin disease for at least 5 years.

Drug Safety and Availability. US Food and Drug Administration.
Patrizi A, Raone B, Ravaioli GM: Management of atopic dermatitis: safety and efficacy of phototherapy. Clin Cosmet Investig Dermatol 2015; 5: 511–520.
Keemss K, Pfaff SC, Born M, Liebmann J, Merk HF, von Felbert V: Prospective, randomized study on the efficacy and safety of local UV-free blue light treatment of eczema. Dermatology 2016; 232: 496–502.
Becker D, Langer E, Seemann M, Seemann G, Fell I, Saloga J, Grabbe S, von Stebut E: Clinical efficacy of blue light full body irradiation as treatment option for severe atopic dermatitis. PLoS One 2011; 6:e20566.
Krutmann J, Medve-Koenigs K, Ruzicka T, Ranft U, Wilkens JH: Ultraviolet free phototherapy. Photodermatol Photoimmunol Photomed 2005; 21: 59–61.
Department of Health, E.Y. National Health Insurance Evaluation and Projections. Taiwan, 1998, DoH, 1.
Cheng TM: Taiwan’s new national health -insurance program: genesis and experience so far. Health Aff (Millwood) 2003; 22: 61–76.
Newman TB, Wickremasinghe AC, Walsh EM, Grimes BA, McCulloch CE, Kuzniewicz MW: Retrospective cohort study of phototherapy and childhood cancer in Northern California. Pediatrics 2016; 137:e20151354.
Brewster DH, Tucker JS, Fleming M, Morris C, Stockton DL, Lloyd DJ, Bhattacharya S, Chalmers JW: Risk of skin cancer after neonatal phototherapy: retrospective cohort study. Arch Dis Child 2010; 95: 826–831.
Contact Dermatitis: American Academy of Dermatology.
Liu CY, Hung YT, Chuang YL: Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manage 2006; 14: 1–22.
Liebmann J, Born M, Kolb-Bachofen V: Blue-light irradiation regulates proliferation and differentiation in human skin cells. J Invest Dermatol 2010; 130: 259–269.
Fischer MR, Abel M, Lopez Kostka S, Rudolph B, Becker D, von Stebut E: Blue light irradiation suppresses dendritic cells activation in vitro. Exp Dermatol 2013; 22: 558–560.
Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V: Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology 2011; 223: 251–259.
Xiong T, Qu Y, Cambier S, Mu D: The side effects of phototherapy for neonatal jaundice: what do we know? What should we do? Eur J Pediatr 2011; 170: 1247–1255.
Egeberg A, Andersen YM, Gislason G, Skov L, Thyssen JP: Neonatal risk factors of atopic dermatitis in Denmark – Results from a nationwide register-based study. Pediatr Allergy Immunol 2016; 27: 368–374.
Wei CC, Lin CL, Shen TC, Kao CH: Neonatal jaundice and risks of childhood allergic diseases: a population-based cohort study. Pediatr Res 2015; 78: 223–230.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.